Sickle cell disease (SCD), a condition that remains widely misunderstood, underresearched, and underfunded, is the most common inherited blood disorder, affecting an estimated 100,000 people in the United States.
Sickle cell disease (SCD), a condition that remains widely misunderstood, underresearched, and underfunded, is the most common inherited blood disorder, affecting an estimated 100,000 people in the United States.
Sickle cell disease (SCD), a condition that remains widely misunderstood, underresearched, and underfunded, is the most common inherited blood disorder, affecting an estimated 100,000 people in the United States.
The ASH Research Collaborative (ASH RC) Data Hub’s Multiple Myeloma Program can feasibly collect patient data from its participating sites for prospective evidence generation, according to new research presented at the 66th ASH Annual Meeting and Exposition.
Sickle cell disease (SCD), a condition that remains widely misunderstood, underresearched, and underfunded, is the most common inherited blood disorder, affecting an estimated 100,000 people in the United States.
The ASH Research Collaborative (ASH RC) Data Hub’s Multiple Myeloma Program can feasibly collect patient data from its participating sites for prospective evidence generation, according to new research presented at the 66th ASH Annual Meeting and Exposition.
An innovative study of patients with multiple myeloma rapidly accrued a diverse cohort, demonstrated high consent/adherence rates, and assessed COVID-19 outcomes and their impact on quality of life. The research was presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, California, and online.
The ASH Research Collaborative (ASH RC) Data Hub, which was developed to facilitate research and quality improvement through real-world data, accurately correlates sickle cell disease (SCD) genotype with verified diagnoses, validating existing and future clinical data in the ASH RC’s Data Hub, according to new research presented today at the 66th ASH Annual Meeting and Exposition.
ASH Research Collaborative study finds that only one-quarter of patients living with SCD are prescribed a DMT
Presentations highlight how real-world data accelerate research and improve hematology care.
